For example, in estrogen receptor (ER)-positive breast cancer cell lines, upregulation of the PI3K pathway was identified as a consequence of chronic exposure to the CDK4/6 inhibitor palbociclib, which in turn upregulated Cyclin D1. This evidence concerns the gene ESR1 and breast carcinoma.